|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
What's more, CRBN ablation suppressed osteoclast differentiation and rescued diabetic bone loss in vivo, accompanied with decreased receptor activator of NF-kB ligand (RANKL), RANKL/osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) levels, as well as improved AMP-activated kinase (AMPK) α/acetyl-CoA carboxylase (ACC)αactivation.
|
29353038 |
2018 |
|
MYELODYSPLASTIC SYNDROME
|
0.030 |
Biomarker
|
group |
BEFREE |
We use the <i>Crbn</i><sup>I391V</sup> model to demonstrate that the in vivo therapeutic activity of lenalidomide in del(5q) myelodysplastic syndrome can be explained by heterozygous expression of Ck1α in del(5q) cells.
|
30064974 |
2018 |
|
Childhood Myelodysplastic Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
We use the <i>Crbn</i><sup>I391V</sup> model to demonstrate that the in vivo therapeutic activity of lenalidomide in del(5q) myelodysplastic syndrome can be explained by heterozygous expression of Ck1α in del(5q) cells.
|
30064974 |
2018 |
|
Adult Myelodysplastic Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
We use the <i>Crbn</i><sup>I391V</sup> model to demonstrate that the in vivo therapeutic activity of lenalidomide in del(5q) myelodysplastic syndrome can be explained by heterozygous expression of Ck1α in del(5q) cells.
|
30064974 |
2018 |
|
Distal monosomy 3p syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We suggest that 3p- syndrome associated features are primarily caused by loss of CNTN4 and CRBN, with loss of CHL1 probably having an additional detrimental effect on the cognitive functioning of the present patient.
|
17036314 |
2006 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM).
|
31271281 |
2019 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also demonstrated that treatment with a pan-PIM kinase inhibitor resulted in increased expression of cereblon, and that knockdown of cereblon via a shRNA lentivirus abolished the effects of PIM kinase inhibition on the degradation of IKZF1 and IKZF3 and myeloma cell apoptosis, demonstrating a central role of cereblon in pan-PIM kinase inhibitor-mediated down-regulation of IKZF1 and IKZF3 and myeloma cell killing.
|
30312729 |
2019 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To determine whether the traditional Chinese medicine arsenic trioxide, could potentiate sensitivity of multiple myeloma (MM) cells to lenalidomide and identify the mechanism by which this happens, the present study investigated how arsenic trioxide affected CRBN on MM cell lines and examined the anti-myeloma effect and mechanism in the combination of arsenic trioxide and lenalidomide.
|
28927072 |
2017 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, our data argue against the use of CRBN and its downstream targets as predictive biomarkers of IMiD response in MM and confirm clonal evolution patterns during lenalidomide resistance.
|
29718735 |
2019 |
|
Multiple Myeloma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This strategy also appeared to be more broadly applicable as SGC-CBP30 could re-sensitize two resistant HMCLs with low but detectable CRBN expression to lenalidomide, suggesting that targeting CBP/E300 is a promising approach to restore IMiD sensitivity in MM with detectable CRBN expression.
|
30741931 |
2019 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
CTD_human |
This dual assay demonstrated superior Cereblon IHC measurement in MM samples compared with the single IHC assay using a published commercial rabbit polyclonal Cereblon antibody and could be used to explore the potential utility of Cereblon as a biomarker in the clinic.
|
26186254 |
2017 |
|
Multiple Myeloma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM.
|
28083618 |
2016 |
|
Multiple Myeloma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that, similar to the treatment of MM, high levels of full-length CRBN mRNA in lower risk 5q- patients are necessary for the efficacy of lenalidomide.
|
25284710 |
2015 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate that the Cereblon-mediated immunomodulatory properties of lenalidomide are maintained in lenalidomide-refractory MM patients and may contribute to immune-mediated killing of MM cells.
|
30338042 |
2018 |
|
Intellectual Disability
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that enhanced autoubiquitination and degradation account for the defect in CRBN activity that leads to mental retardation.
|
23983124 |
2013 |
|
Mental Retardation
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that enhanced autoubiquitination and degradation account for the defect in CRBN activity that leads to mental retardation.
|
23983124 |
2013 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Therapeutically, CRBN engagers have the potential for broad applications in cancer and immune therapy by specifically reducing protein expression through targeted ubiquitin-mediated degradation.
|
29449372 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Therapeutically, CRBN engagers have the potential for broad applications in cancer and immune therapy by specifically reducing protein expression through targeted ubiquitin-mediated degradation.
|
29449372 |
2018 |
|
Constipation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The presence of CRBN AA (rs6768972) or TT (rs1672753) genotypes was associated with about 333-fold and 250-fold lower risk of constipation in the course of therapy (OR = 0·003; OR = 0·004, respectively).
|
31115923 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.020 |
Biomarker
|
disease |
BEFREE |
The pharmacology of iberdomide (CC-220), a cereblon (<i>CRBN</i>) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.
|
29945920 |
2018 |
|
Intellectual Disability
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The nonsense mutation, R419X, causes deletion of 24 amino acids at the C-terminus of CRBN, leading to mild ID.
|
26188093 |
2015 |
|
Mild Mental Retardation
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
The mutation of human cereblon gene (CRBN) is revealed to be related with mild mental retardation.
|
17380424 |
2008 |
|
Intellectual Disability
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The gene coding cereblon (CRBN) was originally identified in genetic linkage analysis of mild autosomal recessive nonsyndromic intellectual disability.
|
27329811 |
2016 |
|
Multiple Myeloma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The description of their cereblon-mediated mechanism of action was a hallmark in MM research.
|
30696815 |
2019 |
|
Multiple Myeloma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The data suggest that expression of CRBN protein in MCs assessed using the IHC is a feasible approach to predict the response of IMiDs in MM patients.
|
24687382 |
2014 |